AbbVie stock has demonstrated a remarkable capacity for rapid appreciation, recording a more than 50% increase in under two months during 2020. Since 2016, the shares have embarked on seven distinct rallies that exceeded 30% within comparable time frames, including significant surges in 2017 and again in 2024. This pattern underscores the potential for another powerful upswing, particularly as the company continues to expand its immunology and oncology franchises. Investors will be watching closely for data readouts from late‐stage trials in atopic dermatitis and rheumatoid arthritis, as positive outcomes could serve as catalysts for the next major breakout.

AbbVie management is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, with a fireside chat beginning at 10:15 a.m. Central time. The live audio webcast will be available via the Investor Relations section of the AbbVie website, with an archived recording posted later the same day. The presentation is expected to cover the company’s pipeline progress in neuroscience and eye care, updates on the integration of its Allergan Aesthetics portfolio, and financial guidance for fiscal 2026. Market participants will be tuning in for any forward‐looking commentary on capital allocation priorities, including share repurchase strategies and potential acquisitions.